Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment approach promising for lymphoma patients in the developing world

08.07.2008
ESMO Conference Lugano, July 3-6, 2008, Lugano, Switzerland

Preliminary results suggest that patients with aggressive non-Hodgkin's lymphoma in the developing world might benefit from a modified chemotherapy regimen, researchers say.

At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, a group headed by Prof. Hamdy Azim from Cairo University reports that giving these patients chemotherapy every 2 weeks, rather than every 3 weeks as usual, improved treatment outcomes.

The standard regimen in this case is called CHOP (chemotherapy regime), which is given every 3 weeks. In the developed world, CHOP is administered in combination with an antibody therapy called rituximab.

... more about:
»CHOP »Treatment »developing »regimen

But many patients in developing countries, including Egypt where this study was conducted, cannot afford this treatment, so they are offered CHOP alone.

"We hypothesized that if CHOP or a CHOP-like regimen was given every two weeks instead of three, a superior outcome could be achieved," says Dr. Hatem A. Azim Jr, who presented these results at ECLU.

To see if this was the case, they analyzed five trials that compared CHOP to regimens given every two weeks. Using two statistical analyses, they showed that regimens every two weeks had superior response rate, disease-free and overall survival; however in one method, the response rate analysis did not reach statistical significance.

"We believe that this work could provide good evidence to support the use of the 2-weekly regimen," Dr. Azim Jr said. One issue that remains to be assessed is how well patients tolerate the more intense treatment, he noted.

"Patients on the 2-weekly regimens have to receive injections with 'growth factors' to ensure that severe toxicities to the white blood cells do not occur," he said. "Even so, the cost of these injections per cycle is much lower than that of rituximab. The preliminary results are encouraging in providing patients who cannot afford the cost of rituximab, a better alternative than CHOP."

Vanessa Pavinato | EurekAlert!
Further information:
http://www.esmo.org

Further reports about: CHOP Treatment developing regimen

More articles from Life Sciences:

nachricht Immune Defense Without Collateral Damage
23.01.2017 | Universität Basel

nachricht The interactome of infected neural cells reveals new therapeutic targets for Zika
23.01.2017 | D'Or Institute for Research and Education

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>